Adult vagina botryoid embryonal rhabdomyosarcoma

Summary

Adult vagina botryoid embryonal rhabdomyosarcoma (MONDO:0004013) is a disease. A subtype of botryoid-type embryonal rhabdomyosarcoma of the vagina — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult vagina botryoid embryonal rhabdomyosarcoma
Mondo ID	MONDO:0004013
DOID	DOID:6848
NCIT	C40267
UMLS	C1515893
MedGen	272994
GARD	0023775
Is cancer (heuristic)	no

Also known as: adult botryoid-type embryonal rhabdomyosarcoma of the vagina · adult sarcoma Botryoides of the vagina · botryoid-type embryonal rhabdomyosarcoma of the vagina of adults

Disease family

This is a subtype of botryoid-type embryonal rhabdomyosarcoma of the vagina. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › soft tissue sarcoma › rhabdomyosarcoma › embryonal rhabdomyosarcoma › botryoid rhabdomyosarcoma › botryoid-type embryonal rhabdomyosarcoma of the vagina › adult vagina botryoid embryonal rhabdomyosarcoma

Related subtypes (1): childhood vagina botryoid rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.